Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018044468) COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/044468 International Application No.: PCT/US2017/044922
Publication Date: 08.03.2018 International Filing Date: 01.08.2017
IPC:
A61K 38/08 (2006.01) ,A61K 31/137 (2006.01) ,A61K 31/593 (2006.01) ,A61K 9/00 (2006.01) ,A61K 47/10 (2017.01) ,A61K 9/08 (2006.01) ,A61K 47/44 (2017.01) ,A61P 5/20 (2006.01)
[IPC code unknown for A61K 38/08][IPC code unknown for A61K 31/137][IPC code unknown for A61K 31/593][IPC code unknown for A61K 9][IPC code unknown for A61K 47/10][IPC code unknown for A61K 9/08][IPC code unknown for A61K 47/44][IPC code unknown for A61P 5/20]
Applicants:
WISCONSIN ALUMNI RESEARCH FOUNDATION [US/US]; 614 Walnut Street Madison, WI 53726, US
Inventors:
DELUCA, Hector, F.; US
CLAGETT-DAME, Margaret; US
PLUM, Lori, A.; US
Agent:
MCBRIDE, M., Scott; US
TAKEN, Michael, E.; US
WILLIAMS, Edward, J.; US
OLEJNICZAK, Aaron, T.; US
KUBORN, Joseph, D.; US
Priority Data:
62/381,37230.08.2016US
62/422,42515.11.2016US
Title (EN) COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM
(FR) COMBINAISON D'UNE FAIBLE DOSE DE 2-MÉTHYLÈNE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMINE D3 ET D'AGENTS CALCIMIMÉTIQUES POUR TRAITER UNE HYPERPARATHYROÏDIE SECONDAIRE
Abstract:
(EN) Disclosed are pharmaceutical compositions and methods of combination therapy that include or utilize low doses of 2-methylene-19-nor-(20S)-1α,25- dihydroxyvitamin D3 and a calcimimetic to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism.
(FR) L'invention concerne des compositions pharmaceutiques et des procédés de traitement combiné qui comprennent ou utilisent de faibles doses de 2-méthylène-19-nor-(20S)-1α,25-dihydroxyvitamine D3 et un agent calcimimétique pour traiter et/ou prévenir l'hyperparathyroïdie secondaire et/ou ses symptômes associés chez un sujet soufrant d'une hyperparathyroïdie secondaire ou présentant un risque de développer une hyperparathyroïdie secondaire.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)